Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T20:03:36.323Z.
Calculation as of: 2026-10-06T20:03:36.323Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5eb2e86bcba2de742a0c9657979184fcfbe1fcca93de60926014cac74d06dbab
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Nuwellis, Inc.
Market Cap
$2.56M
EV/EBITDA Ratio
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO |
|---|---|---|
| Nuwellis, Inc. (NUWE) | $2.56M | N/A |
| bioAffinity Technologies, Inc. (BIAF)vs › | $2.54M | N/A |
| iSpecimen Inc. (ISPC)vs › | $2.69M | N/A |
| Jaguar Health, Inc. (JAGX)vs › | $2.44M | N/A |
| Onconetix, Inc. (ONCO)vs › | $2.37M | N/A |
| Moleculin Biotech, Inc. (MBRX)vs › | $2.38M | N/A |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH)vs › | $2.38M | N/A |
| FibroBiologics, Inc. Common Stock (FBLG)vs › | $2.37M | N/A |
| IceCure Medical Ltd (ICCM)vs › | $2.93M | N/A |
| Creative Medical Technology Holdings, Inc. (CELZ)vs › | $2.32M | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
